retatrutide fatty liver study nonalcoholic steatohepatitis trial significantly improved health in patients with non-alcoholic liver disease Retatrutide approval: FDA status, clinical – retatrutide nonalcoholic fatty liver disease

Author contributions John Andraos was responsible for the idea of this review article

The metabolic benefits of extended use also deserve attention

Phase 2 clinical research published in 2023 documented metabolic effects that exceeded those reported for any prior incretin agonist

retatrutide has Phase 3 data but no regulatory submission yet

Super Bowl night featured thrilling sports action, electrifying music and lavish, star-studded commercials

Research comparing mice treated with GLP-1 medications versus those on calorie restriction with similar weight loss showed the GLP-1 group had substantially greater reductions in liver fat 19